Table 1 Characteristics of included studies
First author | Year | Study | Study design | Phase | Tumor type | Treatments | Sample size | Median follow-up (month) |
|---|---|---|---|---|---|---|---|---|
Altorki [21] | 2021 | NCT02904954 | single-centre, open-label, randomised, controlled, | 2 | clinical stages I-IIIA NSCLC | neoadjuvant durvalumab alone versus neoadjuvant durvalumab + stereotactic radiotherapy | 60 | 16.9 |
Antonia [22] | 2016 | NCT01928394 | multicentre, open-label | 1/2 | limited-stage or extensive-stage SCLC, had disease progression after at least one previous platinum-containing regimen | Nivolumab versus Nivolumab + ipilimumab | 213 | 198.5 days |
Bang [23] | 2020 | JVDJ | single-arm, non-randomised, multi-cohort | Ia/b | advanced NSCLC | Ramucirumab | 28 | 22.6 |
Boyer [16] | 2021 | KEYNOTE-598 NCT03302234 | randomized, double-blind, | 3 | Metastatic NSCLC PDL1 tumor proportion score >  = 50% | Pembrolizumab versus Pembrolizumab + ipilimumab | 568 | 24.0 |
Felip [24] | 2020 | - | open-label, multicenter, dose-escalation and expansion | 1b | stage IIIB/IV ALK-rearranged NSCLC | Ceritinib + Nivolumab | 36 | 24.6 |
Garassino [25] | 2018 | NCT02087423 | open-label, single-arm | 2 | advanced NSCLC | Durvalumab | 444 | 12.0 |
Gettinger [26] | 2021 | Lung-MAP S1400I NCT02785952 | open-label randomized | 3 | previously treated patients with Stage IV squamous Cell Lung Cancer | Nivolumab + ipilimumab versus Nivolumab | 246 | 29.5 |
Herbst [27] | 2021 | JVDF NCT02443324 | multicohort, non-randomized, open-label, | 1a/b | treatment-naïve, locally advanced unresectable or metastatic NSCLC | ramucirumab + pembrolizumab | 26 | 23.5 |
Hui [28] | 2017 | KEYNOTE-001 NCT01295827 | international, randomized, open-labe | 1 | advanced NSCLC | Pembrolizumab | 101 | 22.2 |
Ikeda [29] | 2020 | TORG1936 /AMBITIOUS jRCTs031190084 | multicenter, single-arm | 2 | NSCLC with idiopathic interstitial pneumonias | atezolizumab | 17 | 3.0 |
Jotte [30] | 2020 | IMpower131 NCT02367794 | global, open-labe | 3 | stage IV squamous NSCLC | atezolizumab + carboplatin + paclitaxel versus atezolizumab + carboplatin + nabpaclitaxel versus carboplatin + nab-paclitaxel | 1000 | 18.1 |
Juergens [31] | 2020 | NCT02537418 | multicenter multi-cohort | 1b | advanced, metastatic, recurrent or unresectable SCLC | durvalumab + tremelimumab + chemotherapy | 22 | 19.6 |
Kanda [32] | 2016 | (JapicCTI)-132,071 | single-center, open-label | 1b | stage IIIB without indication for definitive radiotherapy, stage IV, or recurrent NSCLC | nivolumab + chemotherapy | 24 | 6 |
Langer [33] | 2016 | KEYNOTE-021 NCT02039674 | randomised, open-label | 2 | advanced NSCLC | Pembrolizumab + chemotherapy versus Chemotherapy | 123 | 10·6 |
Lin [34] | 2020 | DETERRED NCT02525757 | randomised, open-label | 2 | non-metastatic and unresectable NSCLC | atezolizumab | 40 | 15.3 |
Malhotra [35] | 2021 | NCT03026166 | multicenter, open-label | 1–2 | Previously Treated Extensive-Stage SCLC | Rova-T + nivolumab versus Rova-T + nivolumab and ilimumab | 42 | 7.3 |
Mark [36] | 2021 | SAKK 19/17 | multicenter, single-arm, and open-label trial | 2 | locally advanced, stage IIIB to IV, cytology or histology proven NSCLC | durvalumab | 21 | 6.0 |
Mazieres [37] | 2021 | POPLAR NCT01903993 | randomized, open-label | 2 | previously treated advanced NSCLC | Atezolizumab versus Docetaxel | 277 | 48.0 |
Mazieres [37] | 2021 | OAK NCT02008227 | randomized, open-label | 3 | previously treated advanced NSCLC | Atezolizumab versus Docetaxel | 1187 | 48.0 |
Mok [38] | 2019 | KEYNOTE-042 NCT02220894 | multicenter, randomized, open-label | 3 | previously untreated, PD-L1-expressing, locally advanced or metastatic NSCLC | Pembrolizumab versus Chemotherapy | 1274 | 12·8 |
Nishio [39] | 2021 | IMpower132 NCT02657434 | multicenter, randomized, openlabel | 3 | advanced NSCLC | atezolizumab + Chemotherapy versus Chemotherapy | 101 | 17.5 |
Pakkala [40] | 2020 | NCT02701400 | randomized, two-arm, non-comparative | 2 | relapsed SCLC | durvalumab(D) + tremelimumab(T) without SBRT versus SBRT followed D/T | 18 | 5.7 |
Ramalingam [41] | 2022 | JASPER | multicenter, open-label | 2 | advanced (unresectable) or metastatic NSCLC (stage 3B/4) | Niraparib + Pembrolizumab | 38 | 6.0 |
RodrÃguez-Abreu [17] | 2021 | KEYNOTE-189 NCT02578680 | double-blind trial | 3 | metastatic nonsquamous NSCLC without sensitizing EGFR/ ALK alterations | Pembrolizumab + chemotherapy versus Placebo + chemotherapy | 607 | 31.0 |
Schoenfeld [42] | 2022 | NCT02888743 | open-label, multicentre, randomised | 2 | metastatic NSCLC refractory to previous PD(L)-1 therapy | Durvalumab–tremelimumab ± radiotherapy | 78 | 12·4 |
Sezer [43] | 2021 | EMPOWER-Lung 1 NCT03088540 | multicentre, open-label, global | 3 | advanced NSCLC | Cemiplimab versus Chemotherapy | 697 | 13·1 |
Welsh [44] | 2020 | NCT02444741 | prospective randomized | 1/2 | metastatic NSCLC | Pembrolizumab with or without radiation therapy | 100 | 20.4 |
Welsh [45] | 2020 | – | single-center, open-label | 1/2 | Limited-Stage SCLC | Pembrolizumab and chemoradiation | 40 | 23.1 |
Antonia [18] | 2017 | PACIFIC | randomized, double-blind, international | 3 | stage III, locally advanced | Durvalumab versus placebo | 709 | 14.5 |
Barlesi [46] | 2018 | JAVELIN Lung 200 NCT02395172 | open-label, multicentre, randomised | 3 | stage IIIB, IV, or recurrent NSCLC with disease progression after previous platinum doublet treatment | Avelumab group versus Docetaxel | 758 | 18.9 |
Borghaei [47] | 2015 | CheckMate-057 NCT01673867 | randomized, open-label, international | 3 | stage IIIB or IV or recurrent nonsquamous NSCLC after radiation therapy or surgical resection | Nivolumab versus Docetaxel | 555 | – |
Herbst [48] | 2016 | KEYNOTE-010 | open-label, multicentre, randomised | 2/3 | previously treated, PD-L1-positive, advanced NSCLC | Pembrolizumab versus Pembrolizumab versus Docetaxel | 991 | 13.1 |
Horn [19] | 2018 | IMpower133 | double-blind, placebo-controlled, | 3 | Extensive-Stage SCLC | Atezolizumab versus Placebo | 394 | 13.9 |
Paz-Ares [49] | 2019 | CASPIAN NCT03043872 | open-label, multicentre, randomised | 3 | extensive-stage SCLC | Durvalumab + platinum– etoposide versus Platinum–etoposide | 531 | 14.2 |
Reck [20] | 2016 | CA184-156 NCT01450761 | multicenter, randomized, double-blind | 3 | Extensive-Stage SCLC | Chemotherapy/Ipilimumab versus Chemotherapy/Placebo | 954 | 10.5 |
Socinski [50] | 2018 | Impower-150 | international, randomised, open-label | 3 | Metastatic Nonsquamous NSCLC who had not previously received chemotherapy | atezolizumab + BCP versus bevacizumab + carboplatin + paclitaxel (BCP) | 787 | 15.5 |
West [51] | 2019 | Impower-130 | multicentre, randomised, open-label | 3 | metastatic NSCLC | Atezolizumab + chemotherapy versus Chemotherapy | 705 | 19.2 |
Carbone [52] | 2017 | CheckMate-026 | multicentre, randomised, open-label | 3 | Stage IV or Recurrent NSCLC | Nivolumab versus Chemotherapy | 530 | 13.5 |
Total 38 studies | Â | Â | Â | Â | Â | 14,342 | Â | |